Finerenone slows kidney function decline and reduces serious cardiovascular complications in people with chronic kidney disease who do not have diabetes [1].
This finding provides a critical new treatment option for a vast population of patients. While many kidney therapies target those with diabetes, non-diabetic patients have historically faced more limited medical choices.
Researchers from an international study team released the findings on July 12, 2026 [1]. The multi-center study examined how the medication impacts the progression of chronic kidney disease across various global populations [1].
The results indicate that the drug helps preserve kidney function longer than previous standards of care for this specific group [1]. By reducing the risk of serious kidney events and cardiovascular complications, the treatment addresses two of the most dangerous outcomes associated with the disease [1], [2].
The scale of the need for such interventions is significant. Nearly 800 million people worldwide are living with chronic kidney disease [3].
Scientists said the goal of the research was to establish a viable therapy for the majority of patients who lack diabetes, a group that often falls outside the scope of primary clinical trials for kidney medications [1]. The international collaboration allowed researchers to verify the drug's efficacy across different demographics and healthcare systems [1].
“Finerenone slows kidney function decline and reduces serious cardiovascular complications.”
The expansion of finerenone's application to non-diabetic patients fills a significant gap in renal care. Because chronic kidney disease often progresses silently toward failure, a medication that slows decline across a broader patient base could reduce the global reliance on dialysis and kidney transplants.
